Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field [Seeking Alpha]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Seeking Alpha
ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Today, we are going to peak in on Astria Therapeutics, Inc. ( NASDAQ: ATXS for the first time since early in 2023. This clinical stage biotech firm used to be known as Catabasis Pharmaceuticals, Inc., but changed its name to its Recommended For You Recommended For You About ATXS Stock
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Astria Therapeutics to Present at Upcoming Global Angioedema ForumBusiness Wire
- Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology CongressBusiness Wire
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- 3 Swiss Stocks On The SIX Swiss Exchange With Estimated Discounts Up To 45% [Yahoo! Finance]Yahoo! Finance
ATXS
Earnings
- 8/12/24 - Miss
ATXS
Sec Filings
- 8/12/24 - Form S-8
- 8/12/24 - Form 10-Q
- 7/10/24 - Form SC
- ATXS's page on the SEC website